Surrozen, Inc./DE Operating Expenses
Surrozen, Inc./DE (SRZN) reported Operating Expenses of $15.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Surrozen, Inc./DE operating expenses for the quarter ending 2026-06-30 was $15.37M, a 53.70% increase year-over-year.
- Surrozen, Inc./DE operating expenses for the quarter ending 2026-03-31 was $15.46M, a 46.72% increase year-over-year.
- Surrozen, Inc./DE operating expenses for the quarter ending 2025-12-31 was $13.17M, a 42.39% increase year-over-year.
- Surrozen, Inc./DE operating expenses for the quarter ending 2025-09-30 was $11.87M, a 35.36% increase year-over-year.
- Surrozen, Inc./DE operating expenses for fiscal 2025 was $45.57M, a 25.90% increase from fiscal 2024.
- Surrozen, Inc./DE operating expenses for fiscal 2024 was $36.19M, a 20.94% decline from fiscal 2023.
- Surrozen, Inc./DE operating expenses for fiscal 2023 was $45.78M, a 19.46% decline from fiscal 2022.
- Surrozen, Inc./DE operating expenses for fiscal 2022 was $56.84M, a 4.50% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.37M 10-Q · filed 2026-08-06 | $30.83M 10-Q · filed 2026-08-06 | $43.99M derived: sum of 3 quarters · filed 2026-08-06 | $55.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.46M 10-Q · filed 2026-05-06 | $28.62M derived: sum of 2 quarters · filed 2026-05-06 | $40.49M derived: sum of 3 quarters · filed 2026-05-06 | $50.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $13.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $25.04M derived: sum of 2 quarters · filed 2026-03-23 | $35.03M derived: sum of 3 quarters · filed 2026-08-06 | $45.57M 10-K · filed 2026-03-23 |
| 2025-09-30 | $11.87M 10-Q · filed 2025-11-07 | $21.87M derived: sum of 2 quarters · filed 2026-08-06 | $32.40M 10-Q · filed 2025-11-07 | $41.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.00M 10-Q · filed 2026-08-06 | $20.53M 10-Q · filed 2026-08-06 | $29.78M derived: sum of 3 quarters · filed 2026-08-06 | $38.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.53M 10-Q · filed 2026-05-06 | $19.78M derived: sum of 2 quarters · filed 2026-05-06 | $28.55M derived: sum of 3 quarters · filed 2026-05-06 | $37.60M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $9.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $18.02M derived: sum of 2 quarters · filed 2026-03-23 | $27.06M derived: sum of 3 quarters · filed 2026-03-23 | $36.19M 10-K · filed 2026-03-23 |
| 2024-09-30 | $8.77M 10-Q · filed 2025-11-07 | $17.82M derived: sum of 2 quarters · filed 2025-11-07 | $26.95M 10-Q · filed 2025-11-07 | $36.67M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $9.05M 10-Q · filed 2025-08-08 | $18.18M 10-Q · filed 2025-08-08 | $27.90M derived: sum of 3 quarters · filed 2025-08-08 | $39.09M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $9.13M 10-Q · filed 2025-05-09 | $18.85M derived: sum of 2 quarters · filed 2025-05-09 | $30.04M derived: sum of 3 quarters · filed 2025-05-09 | $40.32M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $20.91M derived: sum of 2 quarters · filed 2025-03-31 | $31.19M derived: sum of 3 quarters · filed 2025-03-31 | $45.78M 10-K · filed 2025-03-31 |
| 2023-09-30 | $11.19M 10-Q · filed 2024-11-06 | $21.46M derived: sum of 2 quarters · filed 2024-11-06 | $36.06M 10-Q · filed 2024-11-06 | $50.73M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $10.28M 10-Q · filed 2024-08-12 | $24.87M 10-Q · filed 2024-08-12 | $39.54M derived: sum of 3 quarters · filed 2024-08-12 | $53.14M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $14.59M 10-Q · filed 2024-05-08 | $29.26M derived: sum of 2 quarters · filed 2024-05-08 | $42.87M derived: sum of 3 quarters · filed 2024-05-08 | $56.94M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $14.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | $28.27M derived: sum of 2 quarters · filed 2024-04-10 | $42.35M derived: sum of 3 quarters · filed 2024-04-10 | $56.84M 10-K · filed 2024-04-10 |
| 2022-09-30 | $13.61M 10-Q · filed 2023-11-08 | $27.68M derived: sum of 2 quarters · filed 2023-11-08 | $42.17M 10-Q · filed 2023-11-08 | $57.16M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $14.07M 10-Q · filed 2023-08-09 | $28.57M 10-Q · filed 2023-08-09 | $43.56M derived: sum of 3 quarters · filed 2023-08-09 | $57.27M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $14.49M 10-Q · filed 2023-05-10 | $29.49M derived: sum of 2 quarters · filed 2023-05-10 | $43.19M derived: sum of 3 quarters · filed 2023-05-10 | $55.85M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $28.70M derived: sum of 2 quarters · filed 2023-03-31 | $41.36M derived: sum of 3 quarters · filed 2023-03-31 | $54.39M 10-K · filed 2023-03-31 |
| 2021-09-30 | $13.71M 10-Q · filed 2022-11-14 | $26.36M derived: sum of 2 quarters · filed 2022-11-14 | $39.40M 10-Q · filed 2022-11-14 | $50.23M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $12.66M 10-Q · filed 2022-08-11 | $25.69M 10-Q · filed 2022-08-11 | $36.53M derived: sum of 3 quarters · filed 2022-08-11 | $45.17M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $13.03M 10-Q · filed 2022-05-11 | $23.87M derived: sum of 2 quarters · filed 2022-05-11 | $32.51M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $19.48M derived: sum of 2 quarters · filed 2022-03-28 | $32.81M 10-K · filed 2022-03-28 | |
| 2020-09-30 | $8.64M 10-Q · filed 2021-11-15 | $21.97M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |